XWELL Inc

Análisis de la acción XWELL Inc (XWEL)

$0.589

+0.016 (+2.78%)Al cierre

Loading chart…
Máximo
0.589
Apertura
0.560
Precio medio ponderado por volumen
0.58
Volumen
16.99K
Capitalización
7.36M
Mínimo
0.560
Importe
9.84K
EV/EBITDA, TTM
0.00

XWELL, Inc. is a global wellness company. The Company delivers restorative and health-focused services to travelers through its three operating segments: XpresSpa, XpresTest, and Naples Wax Center. XpresSpa operates spa service locations in major airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the Centers for Disease Control and Prevention's (CDC's) bio-surveillance program. The Naples Wax Center segment operates six locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. Its health wellness beauty services include massage, waxing, facials, stretch, light emitting diode (LED) light therapy, meditation, manicures, pedicures, aromatherapy, anti-aging treatments, compression therapy, and massage chairs. Its subsidiaries include Naples Wax FRM LLC, Quantum Stream Inc., XpresSpa Holdings, LLC, XpresTest, Inc., and others.

www.xwell.com

Análisis de IA of XWELL Inc (XWEL)

Vender

XWELL Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The stock has a current price of $0.59, which is significantly lower than its 52-week high of $2.20, indicating a 73% drop from its peak. Additionally, the RSI is at 28.253, suggesting the stock is oversold, but this does not guarantee a rebound. The company reported a net loss of $22.4 million in Q2 2026, which raises concerns about its profitability. The stock has also seen a 14.72% drop over the last five days, reflecting ongoing negative sentiment.

Métricas de valoración

El PER previsto actual de XWELL Inc (XWEL) es 10.79, frente a su media de 5 años de 0.23.

PER previsto

Muy sobrevalorado
Media 5A P/E
0.23
P/E actual
10.79
Sobrevalorada
4.95
Infravalorada
-4.48

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-1.28
EV/EBITDA actual
0.00
Sobrevalorada
0.40
Infravalorada
-2.96

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.66
P/S actual
0.00
Sobrevalorada
1.33
Infravalorada
-0.01

Cronología de eventos

2026-07-07 (ET)

09:30:00

Xwell Divests XpresSpa and XpresTest for $13M

2026-04-01 (ET)

16:40:00

XWELL CEO Emphasizes Brand Relevance and Market Expansion

2026-02-03 (ET)

08:30:00

Xwell Partners with PieQ for Biosecurity Forecasting Platform

2026-01-08 (ET)

08:30:00

XWELL Expands Global Biosecurity Strategy, Appoints Former CDC Advisor as Senior Advisor

2025-12-18 (ET)

08:20:00

XWELL Opens New Location in New York's Pennsylvania Station

Noticias

Preguntas frecuentes sobre XWEL, respondidas por Alphio AI

XWELL, Inc. is a global wellness company. The Company delivers restorative and health-focused services to travelers through its three operating segments: XpresSpa, XpresTest, and Naples Wax Center. XpresSpa operates spa service locations in major airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the Centers for Disease Control and Prevention's (CDC's) bio-surveillance program. The Naples Wax Center segment operates six locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. Its health wellness beauty services include massage, waxing, facials, stretch, light emitting diode (LED) light therapy, meditation, manicures, pedicures, aromatherapy, anti-aging treatments, compression therapy, and massage chairs. Its subsidiaries include Naples Wax FRM LLC, Quantum Stream Inc., XpresSpa Holdings, LLC, XpresTest, Inc., and others. It operates in the Consumer Non-Cyclicals sector (SERVICES-PERSONAL SERVICES industry).

XWELL Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The stock has a current price of $0.59, which is significantly lower than its 52-week high of $2.20, indicating a 73% drop from its peak. Additionally, the RSI is at 28.253, suggesting the stock is oversold, but this does not guarantee a rebound. The company reported a net loss of $22.4 million in Q2 2026, which raises concerns about its profitability. The stock has also seen a 14.72% drop over the last five days, reflecting ongoing negative sentiment.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar